Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 15 Jun 2016 |
| Orion Corporation completed share acquisitions | 15 Jun 2016 |
| Orion upgrades full-year outlook for 2016 | 15 Jun 2016 |
| Orion Corporation: Acquisition of own shares 14 June 2016 | 14 Jun 2016 |
| Orion Corporation: Acquisition of own shares 13 June 2016 | 13 Jun 2016 |
| Orion Corporation: Acquisition of own shares 10 June 2016 | 10 Jun 2016 |